Diabetes Ther 13 , 389421 (2022)
The result is fewer drinking moments, more alternation between alcoholic and non-alcoholic choices within the same occasion, and a premium on products that deliver satisfaction with less volume
The findings, which showed that these events were rare but significant, particularly in patients using the drugs for weight loss, were published in the Journal of the American Medical Association (JAMA)
Returning to the United States U.S
In mouse models of Parkinson's disease, treatment with NLY01 for five months was protective against neurodegeneration
Wayne Winegarden, Director, PRI Center for Medical Economics and Innovation, said: GLP-1s are among the most promising medical breakthroughs in decades But allowing unauthorised manufacturers to mass market GLP-1 knockoffs outside FDA safeguards creates significant patient safety risks and undermines trust in the healthcare system. Safety and innovation concerns The report cites concerns including poor storage, dosing errors, questionable ingredient sourcing and counterfeit products
